Skip to main content

Table 2 Biochemical indices of HIV-positive patients, HIV-positive patients on antiretroviral drugs and HIV-negative subjects

From: Impact of highly active antiretroviral drug therapy (HAART) on biochemical, hematologic, atherogenic and anthropometric profiles of human immunodeficiency virus patients at a tertiary hospital in Owo, Nigeria

Age-group

HIV+ve (n = 70)

HAART (n = 70)

HIV−ve (n = 70)

Cholesterol (mg/dl)

   

16–25

35.36 ± 4.11a

312.91 ± 19.65c

80.64 ± 12.09b

26–35

32.81 ± 5.54a

317.52 ± 17.64c

83.80 ± 12.37b

36–45

34.75 ± 4.99a

311.79 ± 14.98c

81.33 ± 8.09b

46–55

36.90 ± 5.59a

324.70 ± 21.27c

82.88 ± 4.98b

56–65

39.00 ± 2.94a

314.25 ± 17.39c

76.60 ± 8.22b

Triglyceride (mg/dl)

   

16–25

25.64 ± 5.62a

276.64 ± 14.84c

83.55 ± 15.80b

26–35

27.48 ± 5.65a

276.05 ± 12.87c

83.53 ± 13.20b

36–45

27.00 ± 4.38a

274.08 ± 7.09c

86.61 ± 9.84b

46–55

28.20 ± 5.57a

282.30 ± 15.09c

88.69 ± 16.24b

56–65

31.00 ± 8.08a

280.25 ± 19.27c

88.30 ± 17.40b

HDL-c (mg/dl)

   

16–25

24.70 ± 3.14a

78.46 ± 9.90c

49.18 ± 3.43b

26–35

25.07 ± 3.36a

86.19 ± 9.06c,e

50.00 ± 3.72b

36–45

27.27 ± 4.30a

81.68 ± 7.71c

51.00 ± 4.02b

46–55

27.11 ± 3.26a

89.80 ± 9.66d,e

51.81 ± 3.56b

56–65

26.85 ± 4.55a

87.75 ± 10.81c,e

49.80 ± 3.80b

LDL-c (mg/dl)

   

16–25

6.00 ± 2.68a,d

179.09 ± 10.71c

14.73 ± 8.53b,d,e

26–35

5.33 ± 1.96a

176.05 ± 10.17c

14.40 ± 5.68b,e

36–45

6.21 ± 1.79a,d

175.33 ± 9.38c

13.00 ± 7.17a,e

46–55

7.20 ± 1.55a,d,e

178.40 ± 12.66c

12.38 ± 4.76a,e

56–65

7.00 ± 1.56a,e

170.50 ± 8.39c

9.10 ± 5.43a,e

Fasting plasma glucose (mmol/l)

   

16–25

2.72 ± 0.38a

11.64 ± 1.42c

5.15 ± 0.48b,d

26–35

2.71 ± 0.47a

11.71 ± 1.50c

4.93 ± 0.37b,d

36–45

2.60 ± 0.30a

11.52 ± 2.57c

5.08 ± 0.47b

46–55

2.90 ± 0.32a

11.35 ± 1.32c

5.13 ± 0.48b

56–65

2.83 ± 0.34a,d

11.33 ± 1.23c

5.29 ± 0.61b

  1. Results are presented as mean ± SD (n is as indicated). Values sharing a common superscript down a column are not significantly different (p > 0.05)
  2. HAART HIV-positive patients on highly active antiretroviral therapy, HIV+ HIV-positive patients, HIV− HIV-negative subjects